| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
In HeLa cells expressing GFP-LC3, retro-2 (1 μM; 1-4 hours) induces autophagy and encourages the accumulation of large autophagosomes in the cytoplasm [2]. How the treatment with Retro-2 (1 μM; 0.5–4 hours) gradually raises the amount of LC3-II protein in cells [2]. Transport between autophagosomes and lysosomes is hampered by Retro-2. Autolysosome formation is eliminated by retro-2 [2]. HeLa cell intoxication brought on by ricin and Shiga-like toxins 1 (Stx1) and 2 (Stx2) is inhibited by retro-2 (20 μM; 30 min pretreatment) [1]. Retro-2 prevents non-enveloped viruses like polyomaviruses, papillomaviruses, and adeno-associated viruses from replicating as well as the intracellular parasite Leishmania from invading cells [3].
|
|---|---|
| ln Vivo |
Mice given Retro-2 (2–200 mg/kg; intraperitoneal; daily; for 21 days) were largely shielded from ricin exposure that could have been fatal for their noses. Mice were fully shielded against the ricin challenge by 200 mg/kg of retro-2 [1].
|
| Cell Assay |
Autophagy assay [2]
Cell Types: HeLa Cell Tested Concentrations: 1 μM Incubation Duration: 1 hour, 2 hrs (hours), 4 hrs (hours) Experimental Results: resulted in a significant increase in the number of small and large vesicles. Western Blot Analysis[2] Cell Types: HeLa Cell Tested Concentrations: 1 μM Incubation Duration: 0.5 hrs (hours), 2 hrs (hours), 4 hrs (hours) Experimental Results: Shows that the abundance of LC3-II protein in cells increases over time. |
| Animal Protocol |
Animal/Disease Models: Female balb/c (Bagg ALBino) mouse (pathogen-free 6 weeks old) were injected with ricin (2 μg/kg) [1]
Doses: 2 mg/kg, 10 mg/kg, 20 mg/kg, 200 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; lasted for 21 days. Experimental Results: Protected mice from ricin challenge. |
| References |
|
| Molecular Formula |
C19H16N2OS
|
|---|---|
| Molecular Weight |
320.408143043518
|
| Exact Mass |
320.098
|
| CAS # |
1201652-50-7
|
| PubChem CID |
727405
|
| Appearance |
White to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
461.9±40.0 °C at 760 mmHg
|
| Flash Point |
233.2±27.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
4.16
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QEGJLRIARJEIPG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16N2OS/c1-14-11-12-16(23-14)13-20-18-10-6-5-9-17(18)19(22)21-15-7-3-2-4-8-15/h2-13H,1H3,(H,21,22)
|
| Chemical Name |
2-[(5-methylthiophen-2-yl)methylideneamino]-N-phenylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~780.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (6.49 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (6.49 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.08 mg/mL (6.49 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1210 mL | 15.6050 mL | 31.2100 mL | |
| 5 mM | 0.6242 mL | 3.1210 mL | 6.2420 mL | |
| 10 mM | 0.3121 mL | 1.5605 mL | 3.1210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
